BioCentury
ARTICLE | Clinical News

ChemoCentryx reports Crohn's data

June 2, 2009 2:31 AM UTC

ChemoCentryx Inc. (Mountain View, Calif.) said 500 mg once-daily oral Traficet-EN met the primary endpoint in the first part of the Phase II/III PROTECT-1 trial to treat Crohn's disease. Data from the induction stage of the double-blind, international study in 436 patients showed that significantly more patients receiving the CC chemokine receptor 9 ( CCR9) antagonist experienced Crohn's Disease Activity Index (CDAI) score reductions of at least 70 points at 12 weeks vs. placebo (61% vs. 47%, p=0.039). The company reported that 250 mg Traficet-EN once and twice daily missed the endpoint. ...